Health Care · Pharmaceutical Preparations · Nasdaq · CIK 2075320 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.99Day +0.00%Mkt cap $94MOff 52W high −95.9%Vol (1Y) 241.0%
Daily closing price, split-adjusted to the current basis; 0.4y shown of 113 bars on file. Sampled to 113 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.6% of sh out |
| Days to cover3.0d |
| Top-10 13F concentration98.9% |
| Next report (est.)2026-08-27 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$9.0M |
| ROE−193.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
No return windows available for PLYX.
| Ann. volatility (1Y)241.0% |
| Ann. volatility (3Y)241.0% |
| Sharpe (1Y)−1.48 |
| Sharpe (3Y)−1.48 |
| Max drawdown (1Y)−94.4% |
| Max drawdown (3Y)−94.4% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $13M | 3.50% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 170,673 | $1M | 0.36% | new |
| MILLENNIUM MANAGEMENT LLC | 127,525 | $964,089 | 0.27% | new |
| VANGUARD FIDUCIARY TRUST CO | 104,556 | $790,443 | 0.22% | new |
| STATE STREET CORP | 58,104 | $439,266 | 0.12% | new |
| BlackRock, Inc. | 41,012 | $310,051 | 0.09% | new |
| NORTHERN TRUST CORP | 27,987 | $211,582 | 0.06% | new |
| BANK OF AMERICA CORP /DE/ | 25,881 | $195,660 | 0.05% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.05 | — | — | — |
| 2025-03-31 | — | −$0.11 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-27 is ESTIMATED from filing cadence (median gap 52d) — not company-confirmed.
